Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Tryptamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 8/20 | 0.96 |
| ▸ | HTR2C known ✓ | P28335 | 4/20 | 0.96 |
| ▸ | HTR6 known ✓ | P50406 | 3/20 | 0.96 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.96 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.96 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.96 |
| ▸ | HTR1A known ✓ | P08908 | 4/20 | 0.60 |
| ▸ | HTR2B known ✓ | P41595 | 2/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.96 |
| ▸ | MPO | P05164 | 2/20 | 0.96 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.96 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.96 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.96 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.96 |
| ▸ | CTSK | P43235 | 1/20 | 0.96 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.96 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.96 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tryptamine SCHEMBL28686775 | 1.00 | PMP22 (1.00) | PMP22HTR2AHTR2CHTR6CYP3A4 | |
| Tryptamine SCHEMBL15273159 | 1.00 | PMP22 (1.00) | PMP22HTR2AHTR2CHTR6CYP3A4 | |
| Tryptamine SCHEMBL7928235 | 0.98 | PMP22 (0.96) | PMP22HTR2AHTR2CHTR6CYP3A4 | |
| Tryptamine SCHEMBL7921174 | 0.98 | PMP22 (0.96) | PMP22HTR2AHTR2CHTR6CYP3A4 | |
| Tryptamine SCHEMBL8660762 | 0.98 | PMP22 (0.96) | PMP22HTR2AHTR2CHTR6CYP3A4 | |
| Tryptamine SCHEMBL8714244 | 0.98 | HTR2A (1.00) | PMP22HTR2AHTR2CHTR6CYP3A4 | |
| Tryptamine SCHEMBL26725 | 0.98 | HTR2A (1.00) | PMP22HTR2AHTR2CHTR6CYP3A4 | |
| Tryptamine SCHEMBL29373222 | 0.98 | HTR2A (1.00) | PMP22HTR2AHTR2CHTR6CYP3A4 | |
| Tryptamine SCHEMBL9472063 | 0.96 | HTR2A (0.96) | PMP22HTR2AHTR2CHTR6CYP3A4 | |
| Tryptamine SCHEMBL22127053 | 0.96 | HTR2A (0.96) | PMP22HTR2AHTR2CHTR6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 455 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115433164-A | Nicotinamide derivative, preparation method thereof and application thereof in anti-aging and life prolonging | 南京师范大学 | 2022-12-06 | — | — | CN | claimed |
| CN-115093410-A | Preparation method of beta-carboline compound | 南京工业大学 | 2022-09-23 | — | — | CN | claimed |
| CN-113698402-B | Synthetic method and application of natural alkaloid Arbornamine with anti-inflammatory activity | 华南理工大学 | 2022-03-25 | — | — | CN | claimed |
| CN-113698402-A | Synthetic method and application of natural alkaloid Arbornamine with anti-inflammatory activity | 华南理工大学 | 2021-11-26 | — | — | CN | claimed |
| CN-108530337-B | Indoleamide compound capable of selectively inhibiting gastric cancer cells | 南华大学 | 2020-11-03 | — | — | CN | claimed |
| CN-110483550-A | One kind derivative of rutaecarpin containing trimethoxyphenyl and its application | UNIV SOUTH CHINA | 2019-11-22 | — | — | CN | claimed |
| CN-110156846-A | A kind of preparation process of D-galactosamine hydrochloride | 南京博源医药科技有限公司 | 2019-08-23 | — | — | CN | claimed |
| CN-109134463-A | 5 type phosphodiesterase inhibitors of B-carboline class and its preparation method and application | 山东大学 | 2019-01-04 | — | — | CN | claimed |
| CN-108912035-A | A kind of indole amides class compound having anti-tumor activity | 雷可欣 | 2018-11-30 | — | — | CN | claimed |
| CN-108530337-A | A kind of alternative indole amides class compound for inhibiting stomach cancer cell | 南华大学 | 2018-09-14 | — | — | CN | claimed |
| US-20130197052-A1 | TRYPTAMINE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN GASTROPATHY | UNIVERSITY OF CALCUTTA (IN) | 2013-08-01 | — | — | US | claimed |
| EP-2616439-A1 | TRYPTAMINE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN GASTROPATHY | Council of Scientific & Industrial Research (IN) | 2013-07-24 | — | — | EP | claimed |
| WO-2012035406-A1 | TRYPTAMINE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN GASTROPATHY | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2012-03-22 | — | — | WO | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| EP-0156267-B1 | METHOD FOR THE PREPARATION OF STRICTOZIDIN | GYOGYNÖVENY KUTATO INTEZET (HU) | 1989-08-30 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130197052-A1 | TRYPTAMINE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN GASTROPATHY | HTRA2, AIFM1, SI | HTR2A 88/4885HTR2C 284/4885HTR6 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.